Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Christine Günther, Michael Cross, PhD, Thomas Ernst, MD, Christian Fabisch, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD

Blood (2017) 130 (Supplement 1): 252.

https://doi.org/10.1182/blood.V130.Suppl_1.252.252

Published: 2017

Journal Articles

Increasing the Sensitivity of BCR-ABL Monitoring By Digital PCR By Reducing the Background Noise

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Svilen Tzonev, PhD, Dawne Naomi Shelton, PhD, Michael Cross, PhD, Kathrin Wildenberger, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2016) 128 (22): 3085.

https://doi.org/10.1182/blood.V128.22.3085.3085

Published: 2016

Journal Articles

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Michael Cross, PhD, Oliver Frank, PhD, Frank Giles, MDMB, Andreas Hochhaus, MD, Christian T. Dietz, PhD, Martin C. Müller, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2015) 126 (23): 135.

https://doi.org/10.1182/blood.V126.23.135.135

Published: 2015

Journal Articles

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MDMB, Andreas Hochhaus, MD, Oliver Frank, PhD, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2014) 124 (21): 3143.

https://doi.org/10.1182/blood.V124.21.3143.3143

Published: 2014

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

Journal Articles

A Comparison of Droplet Digital PCR and Quantitative RT-PCR for Low Level BCR-ABL in CML Patients with Molecular Responses

Jacqueline Maier, PhD, Georg-Nikolaus Franke, MD, Karoline Schubert, Kathrin Wildenberger, Michael Cross, PhD, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2014) 124 (21): 1792.

https://doi.org/10.1182/blood.V124.21.1792.1792

Published: 2014

Journal Articles

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Elisabeth Bolton-Gillespie, Mirle Schemionek, Hans-Ulrich Klein, Sylwia Flis, Grazyna Hoser, Thoralf Lange, Margaret Nieborowska-Skorska, Jacqueline Maier, Linda Kerstiens, Mateusz Koptyra, Martin C. Müller, Hardik Modi, Tomasz Stoklosa, Ilona Seferynska, Ravi Bhatia, Tessa L. Holyoake, Steffen Koschmieder, Tomasz Skorski

Blood (2013) 121 (20): 4175–4183.

https://doi.org/10.1182/blood-2012-11-466938

Published: 2013

Includes: Supplemental data

Journal Articles

Low Level BCR-ABL Mutations Below the Detection Limit of Current Standard Screening Techniques Occur Predominantly in the CD34+ Progenitor Cell Compartment in Chronic Phase CML Patients At Diagnosis. A Substudy of the ENEST1st Trial

Jacqueline Maier, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MD, Andreas Hochhaus, MD, Oliver Frank, Dietger Niederwieser, Thoralf Lange

Blood (2012) 120 (21): 1671.

https://doi.org/10.1182/blood.V120.21.1671.1671

Published: 2012

Journal Articles

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Thoralf Lange, MD, Thomas Ernst, MD, Markus Pfirrmann, PhD, Jacqueline Maier, PhD, Martin C. Müller, MD, Franz Gruber, MD, Dietger Niederwieser, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 1679.

https://doi.org/10.1182/blood.V118.21.1679.1679

Published: 2011

Journal Articles

Patients with Imatinib Resistance Harbour Low Level Mutations of the BCR-ABL Kinase Domain Predominantly in the CD34 + Cells.

Jacqueline Maier, Michael Cross, Haifa Kathrin Al-Ali, MD, Rainer Krahl, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2009) 114 (22): 3267.

https://doi.org/10.1182/blood.V114.22.3267.3267

Published: 2009

NARROW

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Increasing the Sensitivity of BCR-ABL Monitoring By Digital PCR By Reducing the Background Noise

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

A Comparison of Droplet Digital PCR and Quantitative RT-PCR for Low Level BCR-ABL in CML Patients with Molecular Responses

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Low Level BCR-ABL Mutations Below the Detection Limit of Current Standard Screening Techniques Occur Predominantly in the CD34+ Progenitor Cell Compartment in Chronic Phase CML Patients At Diagnosis. A Substudy of the ENEST1st Trial

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Patients with Imatinib Resistance Harbour Low Level Mutations of the BCR-ABL Kinase Domain Predominantly in the CD34 + Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only